Table 1. Characteristics of patients involved in cytokine screening.
| Patient | Age (years) | Sex | Stage | Histology | Chemotherapy |
| P0221 | 78 | M | IVA | Adenocarcinoma | 5-Fu + Oxaliplatin + Bevacizumab |
| P0258# | 69 | F | IIIB | Adenocarcinoma | 5-Fu + Oxaliplatin + Bevacizumab |
| P0378# | 57 | F | IVA | Mucus adenocarcinoma | 5-Fu + Oxaliplatin + Bevacizumab |
| P0855 | 64 | M | IIIC | Adenocarcinoma | 5-Fu + Irinotecan + Oxaliplatin + Cetuximab |
| P1061 | 60 | F | IIIB | Adenocarcinoma | 5-Fu + Oxaliplatin + Bevacizumab |
| P1392# | 77 | M | IIIC | Adenocarcinoma | 5-Fu+Irinotecan + Oxaliplatin + Cetuximab |
#Refers to colorectal cancer patients resistant to 5-Fu.